<DOC>
	<DOCNO>NCT01490658</DOCNO>
	<brief_summary>This trial conduct United States America ( USA ) . The aim trial compare repaglinide metformin co-administered tablet combination tablet .</brief_summary>
	<brief_title>Single Dose Pharmacokinetics Repaglinide , Metformin Combination Tablet Fed Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Repaglinide</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Healthy male female volunteer ( female pregnant , lactate breastfeed ) BMI ( Body Mass Index ) 1929 kg/m^2 , inclusive Fasting plasma glucose 70115 mg/dl Subject judge good health basis medical history , physical examination , ECG ( electrocardiogram ) , routine laboratory data Any clinically significant disease history , opinion Investigator , systemic organ disease Clinically significant abnormality prestudy clinical examination laboratory measurement screen Positive result screen Hepatitis B surface antigen , Hepatitis C antibody HIV ( human immunodeficiency virus ) antibody Positive result drug abuse/alcohol screen Any regular use prescription nonprescription drug , include megavitamin herbal supplement regimen , contraceptive , stop least 1 week prior Visit 2 ( trial product dose administration ) duration study Subject currently smoker ( one cigarette per day equivalent ) Use grapefruit grapefruit juice within 7 day trial product dose administration Blood donation , surgery trauma significant blood loss ( 500 mL ) within last 2 month prior dose</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>